ATHA

Athira Pharma Inc

ATHA, USA

Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

https://www.athira.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ATHA
stock
ATHA

Breakout Move: What is the fair value of Pineapple Financial Inc stock now - Fed Meeting & Daily Oversold Stock Bounce Ideas Bộ Nội Vụ

Read more →
ATHA
stock
ATHA

Queen’s Road Capital Commits US$20 Million Convertible Debenture to ATHA Energy TipRanks

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$4

Analyst Picks

Strong Buy

0

Buy

0

Hold

3

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.90

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-24.68 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-22.01 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.12

Low 1

High 0.3

Investors

* Institutions hold a combined 5.06% of the total shares of Athira Pharma Inc

1.

Perceptive Advisors LLC

(1.3699%)

since

2025/06/30

2.

BML Capital Management LLC

(0.8191%)

since

2025/06/30

3.

Vanguard Group Inc

(0.3899%)

since

2025/06/30

4.

Propel Bio Management LLC

(0.3785%)

since

2025/06/30

5.

Simplify Asset Management Inc.

(0.3785%)

since

2025/06/30

6.

Simplify Propel Opportunities ETF

(0.3785%)

since

2025/07/31

7.

Vanguard Total Stock Mkt Idx Inv

(0.2662%)

since

2025/07/31

8.

TANG CAPITAL MANAGEMENT LLC

(0.1521%)

since

2025/06/30

9.

Bank of America Corp

(0.1055%)

since

2025/06/30

10.

BlackRock Inc

(0.0955%)

since

2025/06/30

11.

Pathstone Holdings LLC

(0.0944%)

since

2025/06/30

12.

Vanguard Institutional Extnd Mkt Idx Tr

(0.0787%)

since

2025/07/31

13.

Geode Capital Management, LLC

(0.0776%)

since

2025/06/30

14.

Renaissance Technologies Corp

(0.0611%)

since

2025/06/30

15.

Citadel Advisors Llc

(0.0533%)

since

2025/06/30

16.

UBS Group AG

(0.0516%)

since

2025/06/30

17.

Qube Research & Technologies

(0.0489%)

since

2025/06/30

18.

Fidelity Extended Market Index

(0.0416%)

since

2025/07/31

19.

Two Sigma Advisers, LLC

(0.0391%)

since

2025/06/30

20.

Laird Norton Tyee Trust Co

(0.0323%)

since

2025/06/30

21.

State Street Corp

(0.0272%)

since

2025/06/30

22.

Susquehanna International Group, LLP

(0.0204%)

since

2025/06/30

23.

Advisor Group Holdings, Inc.

(0.0152%)

since

2025/06/30

24.

Northern Trust Corp

(0.0136%)

since

2025/06/30

25.

Fidelity Total Market Index

(0.0121%)

since

2025/07/31

26.

Fidelity Series Total Market Index

(0.01%)

since

2025/07/31

27.

Spartan Extended Market Index Pool F

(0.0079%)

since

2025/07/31

28.

NT Ext Equity Mkt Idx Fd - NL

(0.0068%)

since

2025/06/30

29.

NT Ext Equity Mkt Idx Fd - L

(0.0063%)

since

2025/06/30

30.

Northern Trust Extended Eq Market Idx

(0.0063%)

since

2025/06/30

31.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0053%)

since

2025/06/30

32.

Spartan Total Market Index Pool G

(0.0043%)

since

2025/07/31

33.

Vanguard U.S. Eq Idx £ Acc

(0.0034%)

since

2025/07/31

34.

Blackrock US Eq Mkt Fund CF

(0.0026%)

since

2025/07/31

35.

U.S. Equity Market Fund F

(0.0022%)

since

2025/06/30

36.

State St US Extended Mkt Indx NL Cl C

(0.0022%)

since

2025/08/31

37.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0018%)

since

2025/06/30

38.

Fidelity Nasdaq Composite Index

(0.0017%)

since

2025/07/31

39.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0015%)

since

2024/12/31

40.

Blackstone Alternative Multi-Strategy I

(0.001%)

since

2024/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-1.68

EPS Estimate

-0.13

EPS Difference

-1.55

Surprise Percent

-1192.3077%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Possible Net-Net(4.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.